Company profile RGNX
There is not enough data for RGNX gene therapy to provide analysis
There is not enough data for RGNX gene therapy to provide correlation calculation
There is not enough data for RGNX gene therapy to provide analysis
There is not enough data for REGENXBIO REGENXBIO stock to provide analysis
There is not enough data for REGENXBIO REGENXBIO stock to provide correlation calculation
There is not enough data for REGENXBIO REGENXBIO stock to provide analysis
There is not enough data for REGENXBIO news to provide analysis
There is not enough data for REGENXBIO news to provide correlation calculation
There is not enough data for REGENXBIO news to provide analysis
After 39 days of this quarter the interest is at 114.0. Based on that we can calculate that during remaining 52 days it will total up to 266.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 212 | 320 50.9% QoQ | 350 9.4% QoQ | 374 6.9% QoQ |
| 2020 | 287 35.4% YoY -23.3% QoQ | 246 -23.1% YoY -14.3% QoQ | 214 -38.9% YoY -13.0% QoQ | 367 -1.9% YoY 71.5% QoQ |
| 2021 | 408 42.2% YoY 11.2% QoQ | 485 97.2% YoY 18.9% QoQ | 211 -1.4% YoY -56.5% QoQ | 243 -33.8% YoY 15.2% QoQ |
| 2022 | 384 -5.9% YoY 58.0% QoQ | 395 -18.6% YoY 2.9% QoQ | 275 30.3% YoY -30.4% QoQ | 281 15.6% YoY 2.2% QoQ |
| 2023 | 402 4.7% YoY 43.1% QoQ | 292 -26.1% YoY -27.4% QoQ | 292 6.2% YoY 0.0% QoQ | 298 6.0% YoY 2.1% QoQ |
| 2024 | 114 -71.6% YoY -61.7% QoQ | - | - | - |
The average 5 years interest of gene therapy companies was 24.71 per week. The last year interest of gene therapy companies compared to the last 5 years has changed by -6.43%. The interest for gene therapy companies is seasonal. The last year interest is comparable to 5 years ago. It has changed only by -13.08%.
After 39 days of this quarter the interest is at 242.0. Based on that we can calculate that during remaining 52 days it will total up to 565.0. gene therapy treatments expected interest is significantly higher compared to previous quarter (+137.4%) and same quarter last year (+119.8%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 171 | 154 -9.9% QoQ | 105 -31.8% QoQ | 127 21.0% QoQ |
| 2020 | 115 -32.7% YoY -9.4% QoQ | 148 -3.9% YoY 28.7% QoQ | 68 -35.2% YoY -54.1% QoQ | 111 -12.6% YoY 63.2% QoQ |
| 2021 | 53 -53.9% YoY -52.3% QoQ | 240 62.2% YoY 352.8% QoQ | 101 48.5% YoY -57.9% QoQ | 218 96.4% YoY 115.8% QoQ |
| 2022 | 215 305.7% YoY -1.4% QoQ | 179 -25.4% YoY -16.7% QoQ | 131 29.7% YoY -26.8% QoQ | 289 32.6% YoY 120.6% QoQ |
| 2023 | 257 19.5% YoY -11.1% QoQ | 230 28.5% YoY -10.5% QoQ | 154 17.6% YoY -33.0% QoQ | 238 -17.6% YoY 54.5% QoQ |
| 2024 | 242 -5.8% YoY 1.7% QoQ | - | - | - |
The average 5 years interest of gene therapy treatments was 13.59 per week. The last year interest of gene therapy treatments compared to the last 5 years has changed by 40.1%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 72.15%.
There is not enough data for genetic defects treatment to provide analysis
There is not enough data for genetic defects treatment to provide correlation calculation
There is not enough data for genetic defects treatment to provide analysis
There is not enough data for NAV Technology Platform to provide analysis
There is not enough data for NAV Technology Platform to provide correlation calculation
There is not enough data for NAV Technology Platform to provide analysis
There is not enough data for wet age-related macular degeneration treatment to provide analysis
There is not enough data for wet age-related macular degeneration treatment to provide correlation calculation
There is not enough data for wet age-related macular degeneration treatment to provide analysis